Scotiabank analyst George Farmer maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a price target of $1.40. The company’s shares closed yesterday at $0.25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Farmer is an analyst with an average return of -8.1% and a 33.33% success rate. Farmer covers the Healthcare sector, focusing on stocks such as Tempest Therapeutics, Adaptimmune Therapeutics, and Inmune Bio.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptimmune Therapeutics with a $1.67 average price target, implying a 568.00% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $3.00 price target.
ADAP market cap is currently $75.55M and has a P/E ratio of -0.86.
Read More on ADAP:
- Promising Growth Prospects and Strategic Advancements Drive Buy Rating for Adaptimmune Therapeutics
- Adaptimmune price target lowered to $1 from $1.50 at Wells Fargo
- Adaptimmune price target lowered to 46c from $1 at Barclays
- Adaptimmune Therapeutics Reports Q1 2025 Earnings
- ADAP Earnings Report this Week: Is It a Buy, Ahead of Earnings?